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Letters to the Editor 287Breast cancer hetero geneity may explain
peaks in recurrenceDear Editor
Dr. Retsky’s1 explanation for the early peak in
recurrence rate in the early period after surgery
is quite plausible and most interesting. Another
possible explanation is the heterogeneity of the
disease. There is variability in the rate of
growth of breast cancers, with the more aggres-
sive tumors recurring early. These are then
removed from the at-risk population, leaving
tumors that grow more slowly. Assuming at least
a moderate proportion of aggressive tumors the
effect would be a clear early peak in the recur-
rence rate. The longer term recurrence rate
would be much lower than that in the early
period following surgery. The rub, of course, is
that today’s science does not enable very
doi: 10.1016/j.ijsu.2005.10.011Bradford-Hill Criteria pro
for controversial theory
Dear Editor
Retsky et al.’s paper1 raises important questions
about the possible role of surgery in promotingaccurate predictions of which tumors will recur
early.
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angiogenesis in early breast cancers. This is
another piece of evidence relevant to the question
of whether screening for cancers in women under
50 is beneficial (reduces mortality) or possibly
